Calidi Biotherapeutics effects 1-for-16 reverse stock split to maintain NYSE American listing

Calidi Biotherapeutics, Inc.

Reverse stock split at 1-for-16 ratio effective July 30, 2026; trading begins July 31 under symbol CLDI.
Post-split shares outstanding: ~2.45M Common Stock and 9,375 Non-Voting Common Stock.
Split approved by stockholders on June 12, 2026; no fractional shares issued.
New CUSIP number 320703 507 assigned to Common Stock.
Purpose: increase per-share price and support continued listing on NYSE American.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.